MBX
MBX Biosciences, Inc.Company Information
- Company Name
- MBX Biosciences, Inc.
- CIK
- CIK0001776111
- Category
- <br>Emerging growth company
- Ticker: Exchange
- MBX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MBX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-13
- Last sale
- 2026-08-04
- Shares purchased (TTM)
- 725,166
- Shares sold (TTM)
- 71,211
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 54,842,955
- Shares outstanding
- 47,696,363
- Ownership
- 114.98%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -6.12%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||
| Series A Convertible Preferred Stock | - | - | - | - | - | - | 0 | 4 | ||||||
Assets Current | ||||||||||||||
| Series B Convertible Preferred Stock | - | - | - | - | - | - | 0 | 11 | ||||||
| Cash And Cash Equivalents At Carrying Value | 54 | 45 | 75 | 223 | 40 | 30 | 49 | 133 | ||||||
| Marketable Securities Current | 364 | 395 | 298 | 169 | 185 | 211 | 213 | 144 | ||||||
| Prepaid Expense And Other Assets Current | 9 | 9 | 8 | 6 | 4 | 3 | 5 | 4 | ||||||
| Assets Current | 428 | 449 | 382 | 398 | 229 | 244 | 267 | 281 | ||||||
| Property Plant And Equipment Net | 5 | 3 | 3 | 2 | 2 | 2 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 436 | 453 | 385 | 400 | 232 | 246 | 269 | 282 | ||||||
Liabilities Current | ||||||||||||||
| Accounts Payable Current | 4 | 7 | 3 | 4 | 6 | 4 | 5 | 5 | ||||||
| Accrued Liabilities Current | 19 | 7 | 12 | 8 | 6 | 6 | 6 | 6 | ||||||
| Operating Lease Liability Current | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 24 | 15 | 15 | 12 | 12 | 10 | 11 | 11 | ||||||
| Operating Lease Liability Noncurrent | 3 | 0 | 0 | 0 | 1 | - | 0 | 0 | ||||||
| Liabilities | 26 | 15 | 16 | 13 | 12 | 11 | 11 | 11 | ||||||
Stockholders Equity | ||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Redeemable Noncontrolling Interest Equity Preferred Carrying Amount | - | - | - | - | - | - | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 696 | 686 | 593 | 590 | 400 | 397 | 395 | 393 | ||||||
| Retained Earnings Accumulated Deficit | -285 | -248 | -224 | -202 | -181 | -161 | -138 | -122 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | 410 | 438 | 369 | 388 | 219 | 235 | 257 | 271 | ||||||
| Liabilities And Stockholders Equity | 436 | 453 | 385 | 400 | 232 | 246 | 269 | 282 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | 0 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | - | 0 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 48 | 48 | 45 | 45 | 34 | 33 | 33 | 33 | ||||||
| Shares Outstanding | 48 | 48 | 45 | 45 | 34 | 33 | 33 | 33 | ||||||
| Temporary Equity Shares Outstanding | - | 0 | 0 | 0 | 0 | 0 | - | 0 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMBX Biosciences, Inc. (MBX) — SEC Financial Statements & Analysis
MBX Biosciences, Inc. (MBX) is a pharmaceutical preparations company, incorporated in DE. MBX Biosciences, Inc. trades on Nasdaq as: MBX. MBX Biosciences, Inc. (MBX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, MBX Biosciences, Inc. carries a market cap of $2.63B, a P/E ratio of -25.24x, a P/B ratio of 6.43x, an enterprise value of $2.58B, and an EV/EBITDA multiple of -21.91x. On profitability, it posts a Return on Equity (ROE) of -33.17%, a Return on Assets (ROA) of -31.25%, and a Return on Invested Capital (ROIC) of -44.09%. Per share, it reports EPS of $-2.19, diluted EPS of $-2.19, free cash flow per share of $-1.79, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -0.88% year-over-year and EPS growth of -30.49% year-over-year. On the balance sheet, it maintains a current ratio of 18.08x, a quick ratio of 17.69x, working capital of $404.20M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, free cash flow of $-85.20M (TTM), and net debt of $-54.12M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.63B
- P/E TTM
- -25.24x
- EPS TTM
- $-2.19
- P/B TTM
- 6.43x
- ROE TTM
- -33.17%
- ROA TTM
- -31.25%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-85.20M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is MBX Biosciences, Inc. in?
MBX Biosciences, Inc. (MBX) operates in the Pharmaceutical Preparations industry.
What exchange does MBX trade on?
MBX Biosciences, Inc. (MBX) trades on the Nasdaq.
Where is MBX Biosciences, Inc. incorporated?
MBX Biosciences, Inc. is incorporated in DE.
When was MBX Biosciences, Inc. (MBX)'s most recent SEC filing?
MBX Biosciences, Inc. (MBX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is MBX's market cap?
MBX Biosciences, Inc. (MBX) has a market capitalization of $2.63B as of 2026-06-30.
What is MBX's EPS (earnings per share)?
MBX Biosciences, Inc. (MBX)'s trailing twelve month EPS is $-2.19 as of 2026-06-30.
What is MBX's ROE (return on equity)?
MBX Biosciences, Inc. (MBX)'s trailing twelve month Return on Equity (ROE) is -33.17% as of 2026-06-30.
What is MBX's ROA (return on assets)?
MBX Biosciences, Inc. (MBX)'s trailing twelve month Return on Assets (ROA) is -31.25% as of 2026-06-30.
What is MBX's ROIC (return on invested capital)?
MBX Biosciences, Inc. (MBX)'s trailing twelve month Return on Invested Capital (ROIC) is -44.09% as of 2026-06-30.
What is MBX's EV/EBITDA?
MBX Biosciences, Inc. (MBX)'s trailing twelve month EV/EBITDA is -21.91x as of 2026-06-30.